Radiopharm Theranostics receives approval to start Phase 1 trial of RAD 202

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Dec 20 2024

0mins

Clinical Study Approval: Radiopharm Theranostics has received ethics approval in Australia to begin a Phase 1 clinical trial for 177Lu-labelled RAD 202, targeting HER2-expressing solid tumors, focusing on safety and preliminary efficacy.
Study Design and Background: The HEAT trial will be an open-label dose escalation study involving multiple centers across Australia, supported by GenesisCare CRO, building on previous data that indicated the safety and therapeutic potential of RAD 202 in cancer treatment.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.